HIV heart shield: drug combo targets weight and cholesterol
NCT ID NCT06317051
First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 16 times
Summary
This study tests two drug combinations in 300 people with HIV who have gained weight or have high cholesterol from their HIV medications. One part compares dapagliflozin (a diabetes drug) to a placebo for weight loss. The other compares a two-statin combo to a single statin for lowering cholesterol. The goal is to reduce heart disease risk without changing HIV treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Health
Melbourne, Victoria, 3084, Australia
-
CART-CRS
Chennai, Tamil Nadu, 600113, India
-
Desmond Tutu Health Foundation
Cape Town, 7925, South Africa
-
HIV-NAT
Bangkok, Thailand
-
Hospital Ramos Mejía
Buenos Aires, Argentina
-
Infectious Diseases Institute, Makerere University
Kampala, Uganda
-
Institute of Human Virology, Nigeria
Abuja, Nigeria
-
St Vincent's Hospital
Sydney, New South Wales, 2010, Australia
-
Universiti Malaya Medical Centre
Kuala Lumpur, Malaysia
-
University of Zimbabwe Clinical Research Centre
Harare, Zimbabwe
Conditions
Explore the condition pages connected to this study.